CHOOLIP & SCIENCES Inc. Stock: price and insider trades · South Korea
압타머사이언스
No insider purchase over the last 90 days. The latest, by 에이치엔제이인베스트먼트, was filed 22 Apr 2026.
CHOOLIP & SCIENCES Inc.: what insiders have been doing
This page follows insider dealings at CHOOLIP & SCIENCES Inc. as filed with DART (FSS), a company from the Health Care sector. Between 2 November 2025 and 2 November 2026, 2 insiders published 3 filings.
Not one open-market sale was filed. On the buying side, 2 insiders reported 3 purchases. The totals do not cover 3 filings with an undisclosed amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant.
Across the 2,655 companies tracked on its exchange, the median is 7 filings; at 3 filings, this issuer sits below that mark. Our records for CHOOLIP & SCIENCES Inc. go back to 2026, with 3 purchases and no sales on the open market in total.
The clock since the last published purchase (22 April 2026) now reads 202 days. The median gap between a trade and its publication by DART (FSS) is 7 days. The shorter that gap, the sooner other investors can see what insiders have done.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and UCB. Source: insider filings from DART (FSS). Past trades are no guide to future returns.
Who traded when
BuySaleSince the insiders bought
- -42.1%Entry ₩1,640 · Close at T+90 ₩950
- -41.0%Entry ₩1,806 · Close at T+90 ₩1,066
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Financial data
as of FY 2025FY ended December 2025 · cache
- 5,009,508 sharesKRXDART:20260422000671Canonical exit: 14 Jul 2026 (T+90)
- 12,000,000 sharesShareKRXDART:20260417000401Canonical exit: 9 Jul 2026 (T+90)
- 12,000,000 sharesKRXDART:20260417000380Canonical exit: 9 Jul 2026 (T+90)
3 of 3 declarations
About CHOOLIP & SCIENCES Inc.
Aptamer Science is a company in the healthcare and pharmaceutical sector, listed on the XKRX market. It focuses on developing aptamer-based therapies for various diseases.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
